In this episode of Novel Targets, we take a broad look at a range of new data that has been emerging for the treatment of breast cancer from several recent cancer meetings, and hear from experts who are shaping the future.

This episode is dedicated to the memory of our friend Jody Schoger, one of the founders of the #BCSM breast cancer community.

1. The Metastatic Breast Cancer Project

Not all studies are company sponsored.  Some of them are driven by academics and may involve patients in novel and collaborative ways. Suppose you happen to be a person with metastatic breast cancer… you could have the power to accelerate cancer research in a way that no one else can, as we found in an compelling and candid interview with Dana Farber’s Dr Nikhil Wagle.

The promise of cancer immunotherapy and in particular checkpoint inhibitors that target the PD1 PDL1 signaling pathway is the topic of this episode.

We hear about the latest data presented at the 2015 annual meeting of the American Association for Cancer Research (AACR) in Philadelphia.

Interviews with Dr Julie Brahmer (Johns Hopkins), Dr Leisha Emens (Johns Hopkins) and Dr Ira Mellman (Genentech) take us on a journey that highlights some of the challenges and opportunities.

We also hear from Dr Suzanne Topalian (Johns Hopkins), Dr Antoni Ribas (UCLA) and Dr Pasi Jänne (Dana-Farber Cancer Institute).